Pelish Henry E.

Pelish Henry E., Chief Scientific Officer, has demonstrated a clear selling bias in recent transactions involving Nuvalent Inc. (NUVL), with no recorded purchases in the latest filings. Over 50 reported trades, his total sell activity amounts to $7.44 million, dwarfing his $1.81 million in buys. The most recent transactions, concentrated in March and January 2026, show consistent disposals, including a $2.37 million sale on March 12 and multiple six-figure transactions totaling over $505,000 the following day. Earlier in the year, January saw a cluster of smaller sales ranging from $18,300 to $133,200, while October 2025 included a $1.28 million disposition alongside several smaller transactions. The pattern is punctuated by occasional acquisitions marked as "M" (likely option exercises or awards), such as four separate transactions on March 12, 2026, valued between $48,800 and $215,900. However, these non-open-market acquisitions are overshadowed by the consistent sell-side activity. Notably, all recent transactions involve NUVL, indicating a singular focus on this biopharmaceutical holding. The absence of any buys in the latest data—coupled with the frequency and scale of sales—suggests an ongoing reduction in Pelish's position, though the reasons remain undisclosed in the filings. The dollar-weighted trend leans decisively toward liquidation, with the most aggressive selling occurring in early 2026.